Lumefantrine

Lumefantrine

Clinical data
AHFS/Drugs.com	International Drug Names
MedlinePlus	a609024
Routes of administration	Oral
ATC code	P01BF01 (WHO) (combination with artemether)
Legal status
Legal status	US: C
Identifiers
IUPAC name 2-(Dibutylamino)-1-[(9Z)-2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl]ethanol
CAS Number	82186-77-4^N
PubChem CID	6437380
DrugBank	DB06708^Y
ChemSpider	4941944^Y
UNII	F38R0JR742
KEGG	D03821^Y
ChEBI	CHEBI:156095^Y
ChEMBL	ChEMBL38827^Y
CompTox Dashboard (EPA)	DTXSID3046663
ECHA InfoCard	100.133.797
Chemical and physical data
Formula	C30H32Cl3NO
Molar mass	528.94 g·mol^−1
3D model (JSmol)	Interactive image
Melting point	130 to 132 °C (266 to 270 °F)
SMILES Clc1ccc(cc1)\C=C3\c4c(c2c(cc(Cl)cc23)C(O)CN(CCCC)CCCC)ccc(Cl)c4
InChI InChI=1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15-^Y Key:DYLGFOYVTXJFJP-MYYYXRDXSA-N^Y
^NY (what is this?)  (verify)

Lumefantrine (or benflumetol) is an antimalarial drug. It is only used in combination with artemether. The term "co-artemether" is sometimes used to describe this combination.^[1] Lumefantrine has a much longer half-life compared to artemether, and is therefore thought to clear any residual parasites that remain after combination treatment.^[2]

Lumefantrine, along with pyronaridine and naphthoquine, were synthesized during the Chinese Project 523 antimalaria drug research effort initiated in 1967; these compounds are all used in combination antimalaria therapies.^[3][4][5]

See also

• Artemether/lumefantrine
• Halofantrine

References

1. Toovey S, Jamieson A, Nettleton G (August 2003). "Successful co-artemether (artemether-lumefantrine) clearance of falciparum malaria in a patient with severe cholera in Mozambique". Travel Medicine and Infectious Disease. 1 (3): 177–179. doi:10.1016/j.tmaid.2003.09.002. PMID 17291911.
2. White NJ, van Vugt M, Ezzet F (August 1999). "Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine". Clinical Pharmacokinetics. 37 (2): 105–125. doi:10.2165/00003088-199937020-00002. PMID 10496300. S2CID 72714420.
3. Cui L, Su XZ (October 2009). "Discovery, mechanisms of action and combination therapy of artemisinin". Expert Review of Anti-Infective Therapy. 7 (8): 999–1013. doi:10.1586/eri.09.68. PMC 2778258. PMID 19803708.
4. Benjamin J, Moore B, Lee ST, Senn M, Griffin S, Lautu D, et al. (May 2012). "Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a tolerability, safety, and preliminary efficacy study". Antimicrobial Agents and Chemotherapy. 56 (5): 2465–2471. doi:10.1128/AAC.06248-11. PMC 3346652. PMID 22330921.
5. Laman M, Moore BR, Benjamin JM, Yadi G, Bona C, Warrel J, et al. (December 2014). "Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial". PLOS Medicine. 11 (12): e1001773. doi:10.1371/journal.pmed.1001773. PMC 4280121. PMID 25549086.